Firebrick Pharma Pursued US Pharmacy Expansion
The company moved to bring its Nasodine nasal spray to physical retail shelves across the United States.
Updated on Sept. 29, 2026 in Healthcare
Live Poll
Do you trust the expansion plans of small-cap pharmaceutical companies into new retail markets?
In Q3 2026, Firebrick Pharma announced plans to transition its Nasodine nasal spray from online-only sales to physical retail pharmacy shelves in the United States. The company intends to operate its American business as an independent entity to support this broader distribution strategy.
Why it matters
Firebrick aims to capitalize on significant online demand to expand its market presence and generate new cash flows. This move marks a strategic shift toward establishing a permanent brick-and-mortar footprint in the highly competitive American healthcare retail sector.
Online US sales of Nasodine grew more than 200% during the 2025-26 fiscal year. The company is now pursuing partnerships with regional pharmacy groups that represent a collective total of 700 storefronts.
The players
Firebrick Pharma
This is an Australian pharmaceutical company that specializes in the development of nasal and throat treatments.
Al Moghaddam
He was appointed by Firebrick Pharma to lead its new standalone US entity as it seeks to expand domestic retail presence.
The details
Firebrick Pharma met with more than 20 pharmacy chains during a summit in Boston to secure physical shelf space for its product. The company will operate its US operations as a standalone entity, with the parent organization receiving a 12% royalty and 20% of manufacturing costs from the local venture.
Timeline
August 2026: Firebrick Pharma executives met with retail pharmacy chains in Boston.
Q3 2026: Firebrick Pharma finalized plans to expand Nasodine into US physical retail stores.
2027: Distribution phases for the product rollout are scheduled to begin.
Market Landscape
Firebrick Pharma's expansion mirrors the broader industry shift where direct-to-consumer health brands seek physical retail partnerships to capture wider market share. This move positions the company to compete more aggressively against established over-the-counter medication providers in the US market.
Customers who currently purchase Nasodine online may soon find the product available for immediate pickup at local pharmacy counters. This shift could simplify the purchasing process and improve local accessibility for those seeking the nasal spray.
The takeaway
Retail expansion serves as a critical growth milestone for pharmaceutical brands looking to transition from niche online products to mass-market availability. Consumers should watch for local store inventory updates as distribution phases begin in 2027.
Further reading
For more on industry shifts, visit the Healthcare section.
Live Poll
Do you trust the expansion plans of small-cap pharmaceutical companies into new retail markets?
